Search Results

You are looking at 121 - 130 of 2,748 items for :

  • Refine by Access: All x
Clear All
Full access

Patient-Reported Outcomes in Multiple Myeloma

Stephanie J. Lee

multiple myeloma . N Engl J Med 2003 ; 348 : 1875 – 1883 . 6 American Society of Clinical Oncology . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 7

Full access

Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp

for HCC remains below 20% in the United States. 2 Poor HCC outcomes are largely attributed to low rates of HCC surveillance and high rates of late stage diagnosis. 3 , 4 Accurate HCC staging is important for patient prognostication, treatment

Full access

HSR19-076: A Prospective Study of the Usage of Pain Medication, Cost, Alternative Medication Use, and Outcome by Cancer Patients in Real World

Praveen Adusumilli, Vidya Viswanath, and Raghunadha Rao Digumarthi

Introduction: Perception of pain and the need to treat it is highly variable, even amongst oncologists. Availability of pain specialists is an added advantage. This is an analysis of prescription patterns of pain medication and its outcome in

Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

lack of lymph node sampling. AREN0532 demonstrated an excellent outcome with a high salvage rate for patients with disease relapse using a standardized regimen (DD4A; doxorubicin/vincristine/dactinomycin) and radiation therapy (RT) ( Table 2 ). 8 A

Full access

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

focused on receipt of locoregional treatment, compared with others with N0M0 disease, node-positive disease, or metastatic disease. We also studied survival outcomes among these various subgroups of patients and explored the possible survival benefit

Full access

Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson, and Banu Arun

primary outcome of interest was documentation of a formal recommendation from the medical provider for a genetic counseling session. Using the prospectively maintained Breast Cancer Database Management System housed in the Department of Breast Medical

Full access

Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

surgeon’s ability to achieve a meticulous cancer dissection. This may impair oncologic outcomes, particularly for locally advanced lower rectal cancer in male patients. 2 – 4 A laparoscopic rectal cancer operation results in short-term patient benefits

Full access

Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack

Jason D. Goldman, Amelia Gallaher, Rupali Jain, Zach Stednick, Manoj Menon, Michael J. Boeckh, Paul S. Pottinger, Stephen M. Schwartz, and Corey Casper

measure relative risk of (1) cumulative 30-day mortality, (2) development of SSh, or (3) the combined outcome of cumulative 30-day mortality or development of SSh. Multivariate models were constructed to control for prespecified confounding variables

Full access

Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

pathologic complete response (pCR). 11 HER2 expression was found in 27% of resected locally advanced rectal adenocarcinomas and may be associated with improved outcomes after multimodality therapy. 12 A key potential resistance mechanism in colorectal

Full access

Update on PSA Testing

Mark L. Gonzalgo and H. Ballentine Carter

The use of prostate-specific antigen (PSA) testing for prostate cancer screening has increased dramatically over the past decade. Determining the most efficient way to use PSA testing and how to interpret total PSA levels and changes in PSA values over time remain challenging. Guidelines for early detection of prostate cancer have a direct impact on the number of unnecessary tests performed and are critical for developing a successful screening approach for prostate cancer. The age at which PSA screening should begin, PSA testing intervals, and the importance of understanding fluctuations in PSA values over time are discussed in the framework of recent discoveries in the field. Results from ongoing randomized trials will confirm whether prostate cancer screening is an effective method for reducing deaths from prostate cancer and what approaches will provide the most cost-effective screening strategies.